A20 protein regulates lipopolysaccharide-induced acute lung injury by downregulation of NF-κB and macrophage polarization in rats

YING WANG1*, ZHENJIU SONG2*, JING BI1, JIE LIU1, LIN TONG1, YUANLIN SONG1, CHUNXUE BAI1* and XIAODAN ZHU1*

1Department of Pulmonary Medicine; 2Emergency Department, Zhongshan Hospital, Fudan University, Shanghai Respiratory Research Institute, Shanghai 200032, P.R. China

Received October 12, 2016; Accepted June 8, 2017

DOI: 10.3892/mmr.2017.7184

Abstract. Modulation of inflammation is a crucial component of the development of acute lung injury. A20, a ubiquitin editing enzyme, may regulate cellular inflammatory reactions, particularly those involving the signaling pathway of nuclear factor NF-κB (NF-κB). The present study investigated the mechanism by which A20 downregulated NF-κB and further contributed to macrophage polarization from the M1 to M2 phenotypes in lipopolysaccharide (LPS)-induced lung injury. Sprague-Dawley rats injected with LPS were used in the present study. Bronchoalveolar lavage fluid and lung tissue were collected from each experimental rat. A macrophage cell line was used to test the expression levels of A20. Tumor necrosis factor-α (TNF-α), interleukin-1 beta (IL-1β) and NF-κB activities were assessed by ELISA and polymerase chain reaction. Macrophage phenotypes were assayed using fluorescence-activated cell sorting. Elevated levels of TNF-α, IL-1β, NF-κB and A20 were observed in the macrophages of rats treated with LPS. Furthermore, A20 overexpression inhibited NF-κB DNA binding activity and increased macrophage polarization from the M1 to M2 phenotype in lung macrophages of the NR8383 cell line. It was concluded that the A20 protein in macrophages modulates lung injury induced by LPS. The overexpression of A20 in macrophages may be involved in modulating macrophage polarization. The mechanisms and molecular identification of macrophage polarization activation may provide a basis for the treatment of inflammation in lung injury.

Introduction

According to the Berlin Definition, acute lung injury (ALI) is equal to mild acute respiratory distress syndrome (ARDS) with a partial pressure of oxygen/fraction of inspired oxygen of <300 mmHg and positive end expiratory pressure/continuous positive airway pressure levels of ≥5 cmH2O (1). ARDS is a common cause of mortality in patients suffering from severe pneumonia or avian influenza for example, with the mortality rate being as high as 40-60% (2-4). Despite improvements in supportive treatment, the mortality rate of ARDS remains high (5,6). In addition, there is no effective pharmacological therapy that targets ARDS directly (7). The dominant characteristics of ARDS are proteinaceous pulmonary edema with severe inflammation and gas exchange abnormalities with severe hypoxemia (8). Proinflammatory responses occur in the pathogenesis of lung injury, which indicates that inhibiting inflammatory cytokine secretion may be a therapeutic approach to inhibit the progression of inflammation in ARDS.

Lipopolysaccharide (LPS) is the main cause of ALI in animal models and has been demonstrated to modulate the nuclear factor NF-κB (NF-κB) signaling pathway (9). The NF-κB pathway is an important signaling pathway induced by lung injury (10) and regulates several molecular processes, including apoptotic cell death, cell cycle progression, cell survival and adhesion, and the expression and activation of inflammatory factors, including tumor necrosis factor α (TNF-α) and interleukin 1β (IL-1β) (9,11). In clinical practice, activation of the NF-κB pathway is observed in a number of inflammatory injuries, including rheumatoid arthritis and asthma (12,13). Therefore, it is essential to consider the regulatory mechanism of NF-κB activity for ALI intervention. NF-κB activity is also associated with macrophage polarization (14-16). Macrophages serve a crucial role in the...
immunomodulation of lung injury and function to eliminate invading pathogens by producing cytokines (17). This leads to the damage and impairment of lung function (18). Activated macrophages of different phenotypes are routinely classified as M1 or M2 macrophages (16). Activated M1 macrophages are immune cells of the acute inflammatory response, which produce large amounts of lymphokines and are aggressive against bacteria (19). By contrast, M2 macrophages participate in tissue repair and wound healing (15). A previous study focused on how macrophage polarization in vivo can be manipulated to alter disease outcomes (14).

Preliminary data on A20, a cytoplasmic zinc finger protein, or the A20 binding inhibitor of NF-κB activation families demonstrated that A20 may be involved in the downregulation of NF-κB (13). It has been demonstrated that A20 has the ability to inhibit the activity of NF-κB (13). In addition, A20-deficient mice demonstrate serious inflammatory responses following LPS injury, indicating that A20 may limit the inflammatory reaction through inhibition of the NF-κB response in vivo (20). Furthermore, A20 is reported to downregulate the NF-κB signaling pathway as demonstrated by overexpression in human carcinoma cells (21). Additionally, low expression of A20 may upregulate the expression of TNF-α in macrophages (22).

Several studies demonstrated the activity of A20 in the lung. A20 may serve an inhibitory role in inflammatory responses in airway epithelial cells (23). The studies by Tiesset et al (24) and Onose et al (25) suggest that A20 may have a protective function in the course of infections with Pseudomonas aeruginosa or influenza. However, whether the A20 protein exerts this suppressive effect on NF-κB and inhibits the inflammatory response induced by LPS in the lung remains unknown. Similarly, whether the A20 protein may regulate macrophage polarization remains obscure.

In the present study, it was observed that LPS-induced acute lung damage acted via the modulation and overexpression of A20 which were associated with the progression of macrophage polarization via the inhibition of the NF-κB pathway.

Materials and methods

Animal treatment. A total of 54 male specific pathogen-free Sprague-Dawley rats weighing 250-300 g (8-10 weeks) were assigned to the Laboratory Animal Center, Fudan University (Shanghai, China) in clean conditions with a controlled temperature of 18-26˚C, humidity 40-70%, and 12/12-h light/dark cycle. The animals were given free access to water and food only for 12 h prior to experimentation. The Animal Ethics Committee of Fudan University approved all experimental protocols. All animals were sacrificed following the Guide for the Care and Use of Laboratory Animals published by the National Institutes of Health.

The rats received an injection of PBS or LPS (Escherichia coli O55:B5; Sigma-Aldrich; Merck KGaA, Darmstadt, Germany; cat. no. L2637) via the tail vein. A dose of 10 mg/kg of LPS was dissolved in 1 ml PBS. The control animals were injected with 1 ml PBS. After 1, 2, 4, 6, 8, 12, 24 and 48 h (n=6 each), the rats were treated with intraperitoneal injections of 7.5 ml/kg urethane. The wet-to-dry (W/D) weight ratio of the middle lobe of the right lung was measured as previously described (26).

Bronchoalveolar lavage fluid (BALF). BALF of each experimental rat was collected and was done in the left lung. BALF was centrifuged (600 x g, 10 min at 4˚C; LTPA Cytocentrifuge, Experimental Instrument Factory, Academy of Military Medical Sciences, Beijing, China), and cell-free supernatants were stored at -80˚C. The cell pellet was diluted in PBS, and total cell number was counted with a hemocytometer. Differential cell counts were done with cytocentrifuge preparations stained with Diff-Quik stain at room temperature for 90 sec. Neutrophil populations were determined by counting 300 cells/sample, and a percentage was calculated based on 6 mice per group. Bronchoalveolar lavage protein concentration was measured in the cell-free supernatant by using a bicinechonic acid protein assay kit according to the manufacturer's instruction (Thermo Fisher Scientific, Inc., Waltham, MA, USA).

Cell culture. The Shanghai Institutes for Biological Sciences of the Chinese Academy of Science (Shanghai, China) provided the lung macrophage NR8383 cell line from its cell bank. All cells were preserved in humidified air with 5% CO₂ at 37˚C. Dulbecco's modified Eagle's medium/F-12K (Invitrogen; Thermo Fisher Scientific, Inc.; cat. no. 12100-046) was used to preserve the cells, supplemented with 20% fetal bovine serum (Hyclone; GE Healthcare Life Sciences, Logan, UT, USA; cat. no. SV30087.02), 100 U/ml streptomycin and 100 µl/m penicillin G (Invitrogen; Thermo Fisher Scientific, Inc.; cat no. GB15140-122) with 2.5 g/l NaHCO₃ and 2 mM L-glutamine solution (Sigma-Aldrich; Merck KGaA; cat. no. G7513) at 37˚C in humidified air with 5% CO₂.

Transfection of small interfering RNA (siRNA). Sigma-Aldrich (Merck KGaA) provided the siRNA. The sequence of siRNA for rat A20 is: Sense 5'-CCGGCCAATGTTGTATGGAAACTCGGCCCAGATGAGGCTTTCCATCCAGCTCG GTTTTGG-3', and antisense 5'-AATTTCAAAAAACCAATGGTATGGGAAACTCGGCCAGATGAGGCTTTCCATCCAGCTCG GTTTTGG-3'. For siRNA control (scrambled siRNA, SCR), oligos with no matching GeneBank sequence were used: Sense 5'-GGCGACGACUGCUAAAGAU-3', and antisense 5'-UCCUAACGCGAUAGCUAGAGC-3'. The siRNA oligonucleotide pairs were prepared as 20 µM stocks. For transient transfections, the LipoFectamine™ RNAiMAX kit (Thermo Fisher Scientific, Inc.; cat no. 13778-150) was used on the NR8383 cell line. Following transfection, the cells were left for a further 24 h before they were used for experiments.

A20 plasmid transfection. Mouse A20 (Tnfaip3; gene ID: NM_009397.3) was cloned from mouse cDNA (Beijing ComWin Biotech Co., Ltd.; Beijing, China) with forward primer (5'-GTTGCGAAGCATAACACTGAAAAGG-3') and reverse primer (5'-GGCTGTGACAGGAAGGACTCTA-3') under the following conditions: i) 95˚C for 2 min; ii) 30 cycles of 95˚C for 20 sec, 52˚C for 20 sec and 72˚C for 60 sec; iii) 72˚C for 3 min. The nucleotide sequence was inserted into the pCDH-CMV-MCS-EF1-copGFP vector (System Biosciences, Palo Alto, CA, USA; cat. no. cd511b) at the EcoRI and BamHI restriction sites. The recombinant vector was transfected into the
NR8383 cell line using Lipofectamine™ 2000 (Thermo Fisher Scientific, Inc.; cat. no. 11668-019). Following transfection, the cells were treated with LPS (1 µg/ml) at room temperature for 0.5, 1, 2 and 4 h. The cells were then collected for use.

Histopathology and immunohistochemistry. Subsequent to measurement of the wet weights and examination of the BALF, the lower lobe of the right lung was fixed in 4% formaldehyde at room temperature and paraffin-embedded with the procedure previously described (13), while the upper lobes of the right lung were stored at -80°C. The tissue preparations with paraffin-embedded were cut into 5-µm sections and stained with hematoxylin and eosin to assess the histopathology score. The method of staining and assessment was as previously described (26). Immunostaining of lung tissue was done with 5-µm paraffin sections. Anti-A20 (Cell Signaling Technology, Inc., Danvers, MA, USA; cat. no. 5630) and F4/80 (Abcam, Cambridge, UK; cat. no. ab111101) antibodies were used for staining tissue sections at different time points. Lung tissue was treated twice with fluorescently labeled antibodies; F4/80 (secondary antibody with green fluorescence) and A20 (secondary antibody with red fluorescence), while the nuclei were stained with DAPI. Fluorescent images were captured by a Zeiss LSM 510 META confocal laser-scanning microscope (Carl Zeiss AG, Oberkochen, Germany). The number of A20 and F4/80 positive cells was counted in five randomly selected fields by viewing each slide at a magnification of x400 and the average number in each group was calculated. All procedures are as previously described (13).

NF-κB DNA binding activity assay and cytokine detection. NF-κB DNA binding activity was measured in lung tissue with an ELISA kit from Active Motif (Carlsbad, CA, USA; TransAM® Flexi NFκB p65; cat. no. 40098) and the result was presented as NF-κB optical density (OD). The procedure was performed according to the manufacturer’s protocol. TFN-α (Rat TNF-alpha Quantikine SixPak; R&D Systems, Inc., Minneapolis, MN, USA; cat. no. SRTA00) and IL-1β (Rat IL-1 beta/IL-1F2 Quantikine SixPak; R&D Systems, Inc.; cat. no. SRLB00) levels in the supernatant were measured with ELISA kits. The method was performed according to the manufacturer’s protocol.

Western blot analysis. The procedure for immunoblotting was performed as previously described (27). Proteins were loaded into the lanes of an SDS or tricine-SDS polyacrylamide gel. The proteins were separated and transferred to nitrocellulose membranes (0.45 or 0.22 µm; Schleicher & Schuell; BioScience GmbH, Dassel, Germany). The membranes were blocked with 5% non-fat dry milk in 0.01 M PBS (pH 7.4) and 0.05% Tween-20 (TPBS) at room temperature for 1 h. Subsequently, the membrane was incubated with primary antibodies directed against target proteins overnight at 4°C. The primary antibodies used were: Anti-A20 rabbit monoclonal antibody (A20/TNFAIP3 (D13H3) Rabbit mAb; Cell Signaling Technology, Inc.; Danvers, MA, USA; cat. no. M1701), anti-NF-κB p65 (Abcam; Cambridge, UK; cat. no. ab16502) and GAPDH (R&D Systems, Inc.; cat. no. AF5718). The final dilutions for the primary antibodies were: A20, NF-κB, 1:1,000; and GAPDH, 1:2,000. Following three quick washes in TPBS, the membranes were incubated with secondary antibodies conjugated to horseradish peroxidase (GE Healthcare, Chicago, IL, USA; cat. no. RPN4301) diluted at 1:5,000 in TPBS for 1 h at 4°C. The enhanced chemiluminescence method (GE Healthcare; cat. no. RPN2106) was used to visualize protein bands. The protein expression was quantified using Quantity One software version 4.62 (Bio-Rad Laboratories Inc., Hercules, CA, USA).

RNA extraction and reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Total RNA was isolated from the lung tissues using TRIzol reagent (Thermo Fisher Scientific Inc.; cat. no. 15960618) and treated with RNase-free DNase I (Roche Applied Science, Penzberg, Germany; cat. no. 10104159001). First-strand cDNA was synthesized using Moloney-murine leukemia virus reverse transcriptase (Promega Corporation, Madison, WI, USA; cat. no. M1701) and oligo-dTs (Promega Corporation; cat. no. C1101), which was performed at 42°C for 1 h followed by 70°C for 15 min. Subsequently, the RevertAid™ First Strand cDNA Synthesis kit (Fermentas; Thermo Fisher Scientific, Inc.) was used for the qPCR, under the following conditions: i) 95°C for 30 sec; ii) 40 cycles of 95°C for 5 sec and 60°C for 30 sec. Quantitative analysis was performed with the Applied Biosystems Prism 7500 Sequence Detection System according to the manufacturer’s protocol (Thermo Fisher Scientific, Inc.). The expression levels of target cDNAs were normalized to the endogenous transcription levels of the control and quantification was performed using 2-ΔΔCq (28). The primer sequences are provided in Table I.

Table I. Primers used for polymerase chain reaction.

<table>
<thead>
<tr>
<th>Gene name</th>
<th>Forward</th>
<th>Reverse</th>
<th>Size, bp</th>
</tr>
</thead>
<tbody>
<tr>
<td>A20</td>
<td>GCAGTGTAAGGAGGCTAAC</td>
<td>TGGGGTTCTCTCTGATCTTC</td>
<td>150</td>
</tr>
<tr>
<td>TNF-α</td>
<td>GTGTCCTGAGGCCTCACCC</td>
<td>ACTGATGAGGGAGGAGCCAT</td>
<td>126</td>
</tr>
<tr>
<td>IL-1β</td>
<td>ATCAGCACCTCAGAGCTCC</td>
<td>TCTCTCCCCGATGAGTACGC</td>
<td>195</td>
</tr>
<tr>
<td>β-actin</td>
<td>GAGATTAGTGCCCTGCTCTA</td>
<td>GACTCATCGTACTCCTGCTG</td>
<td>150</td>
</tr>
</tbody>
</table>

TNF-α, tumor necrosis factor α; IL-1β, interleukin 1β.

NF-κB B DNA binding activity assay and cytokine detection. NF-κB DNA binding activity was measured in lung tissue with an ELISA kit from Active Motif (Carlsbad, CA, USA; TransAM® Flexi NFκB p65; cat. no. 40098) and the result was presented as NF-κB optical density (OD). The procedure was performed according to the manufacturer's protocol. TFN-α (Rat TNF-alpha Quantikine SixPak; R&D Systems, Inc., Minneapolis, MN, USA; cat. no. SRTA00) and IL-1β (Rat IL-1 beta/IL-1F2 Quantikine SixPak; R&D Systems, Inc.; cat. no. SRLB00) levels in the supernatant were measured with ELISA kits. The method was performed according to the manufacturer's protocol.

Western blot analysis. The procedure for immunoblotting was performed as previously described (27). Proteins were loaded into the lanes of an SDS or tricine-SDS polyacrylamide gel. The proteins were separated and transferred to nitrocellulose membranes (0.45 or 0.22 µm; Schleicher & Schuell; BioScience GmbH, Dassel, Germany). The membranes were blocked with 5% non-fat dry milk in 0.01 M PBS (pH 7.4) and 0.05% Tween-20 (TPBS) at room temperature for 1 h. Subsequently, the membrane was incubated with primary antibodies directed against target proteins overnight at 4°C. The primary antibodies used were: Anti-A20 rabbit monoclonal antibody (A20/TNFAIP3 (D13H3) Rabbit mAb; Cell Signaling Technology, Inc.; Danvers, MA, USA; cat. no. M1701), anti-NF-κB p65 (Abcam; Cambridge, UK; cat. no. ab16502) and GAPDH (R&D Systems, Inc.; cat. no. AF5718). The final dilutions for the primary antibodies were: A20, NF-κB, 1:1,000; and GAPDH, 1:2,000. Following three quick washes in TPBS, the membranes were incubated with secondary antibodies conjugated to horseradish peroxidase (GE Healthcare, Chicago, IL, USA; cat. no. RPN4301) diluted at 1:5,000 in TPBS for 1 h at 4°C. The enhanced chemiluminescence method (GE Healthcare; cat. no. RPN2106) was used to visualize protein bands. The protein expression was quantified using Quantity One software version 4.62 (Bio-Rad Laboratories Inc., Hercules, CA, USA).

RNA extraction and reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Total RNA was isolated from the lung tissues using TRIzol reagent (Thermo Fisher Scientific Inc.; cat. no. 15960618) and treated with RNase-free DNase I (Roche Applied Science, Penzberg, Germany; cat. no. 10104159001). First-strand cDNA was synthesized using Moloney-murine leukemia virus reverse transcriptase (Promega Corporation; Madison, WI, USA; cat. no. M1701) and oligo-dTs (Promega Corporation; cat. no. C1101), which was performed at 42°C for 1 h followed by 70°C for 15 min. Subsequently, the RevertAid™ First Strand cDNA Synthesis kit (Fermentas; Thermo Fisher Scientific, Inc.) was used for the qPCR, under the following conditions: i) 95°C for 30 sec; ii) 40 cycles of 95°C for 5 sec and 60°C for 30 sec. Quantitative analysis was performed with the Applied Biosystems Prism 7500 Sequence Detection System according to the manufacturer's protocol (Thermo Fisher Scientific, Inc.). The expression levels of target cDNAs were normalized to the endogenous transcription levels of the control and quantification was performed using 2-ΔΔCq (28). The primer sequences are provided in Table I.
Flow cytometry. NR8383 cells were treated with trypsin, resuspended in PBS and stained with 10 μl F4/80 antibodies (15 min at 37°C) or 10 μl anti-cluster of differentiation CD206 (15 min at 37°C). A20 overexpression and A20 knockdown cells [small interfering (si)RNA for A20] were treated with anti-F4/80 and CD206 antibodies. The anti-F4/80 antibody was labeled with fluorescein isothiocyanate (Abcam; cat. no. ab111101) with green fluorescence, while the anti-CD206 antibody was labeled with allopyocyanin (Abcam; cat. no. ab64693) with red fluorescence. The final dilutions for the antibodies were: Anti-F4/80 antibody, 1:100; and anti-CD206 antibody, 1:3,000. The FL2 and FL1 fluorescence was collected in each experiment by gating and acquiring the cell population using a FACSscan flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA). CD206+/F4/80+ cells are M2 macrophages while CD206/F4/80+ cells are M1 macrophages (29).

Statistical analysis. Statistical significance was assessed by analysis of variance (ANOVA) and Student's t-test using SPSS software version 22.0 (IBM Corp., Armonk, NY, USA) and GraphPad Prism 6 (GraphPad Software Inc., La Jolla, CA, USA). One-way ANOVA was used for the analysis of relative quantitative data, with the least significant difference post hoc test. Student's t-test was used for the analysis of independent variables. The data were presented as the mean ± standard
deviation. P<0.05 was considered to indicate a statistically significant difference.

Results

LPS induces acute lung injury in rats. Compared with the control group, the LPS-treated group demonstrated histological features representative of ALI and significant increases in the lung W/D weight ratio, BALF total cell number and BALF protein concentration (P<0.05; data not shown).

Cytokine secretion and NF-κB DNA binding activity are increased by LPS. Following LPS treatment, the levels of TNF-α and IL-1β, and NF-κB DNA binding activity increased in a time-dependent manner (Fig. 1A-C). At the 2 h time-point, the activity reached a first peak (all P<0.05 compared with the control group). In the following 10 h, the levels of TNF-α and IL-1β, and the NF-κB activity decreased gradually but remained increased compared with the control (all P<0.05). Furthermore, at 24 h, the levels of TNF-α and IL-1β increased again (both P<0.05 compared with the control group).

LPS regulates A20 expression in pulmonary tissues. Following treatment with LPS, the mRNA (data not shown) and protein levels of A20 in the lung tissue increased with time (Fig. 1D) and peaked after 2 h (P<0.05 compared with the control group). Subsequently, the levels gradually decreased but were increased compared with the control group (P<0.05). As demonstrated by immunofluorescence staining, the level of A20 also peaked at 2 h and gradually decreased following treatment with LPS, and A20 was expressed in pulmonary macrophages (Fig. 1E).

A20 siRNA increases NF-κB DNA binding activity and upregulates TNF-α and IL-1β secretion. To examine the transfection efficiency, the mRNA and protein expression levels of A20 were measured by RT-qPCR and western blotting, respectively. A20 expression was significantly inhibited in the siA20 (A20 small interfering RNA) group compared with the SCR group throughout (Fig. 2A and B). Following induction by LPS, the NF-κB DNA binding activity and protein expression levels increased in the A20-knockdown macrophages; the highest levels were observed at 1 h (Fig. 2C-E). Subsequently, these levels gradually decreased.

The mRNA levels of TNF-α and IL-1β increased in the A20-knockdown macrophages induced by LPS, and they reached peak levels at 1 h (Fig. 3A and B). Subsequently, they gradually reduced. These results were the same as the protein levels of TNF-α and IL-1β measured by ELISA (Fig. 3C and D).

A20 overexpression inhibits NF-κB DNA binding activity, and decreases TNF-α and IL-1β secretion. To examine the transfection efficiencies, the mRNA and protein expression levels of A20 were measured by RT-qPCR and western blotting, respectively. When compared with vehicle control (VEC), A20 expression was markedly increased (Fig. 4A and B). NF-κB protein expression increased in VEC macrophages...
induced by LPS and reached a peak at 1 h. Subsequently, the expression gradually reduced. However, the NF-κB protein expression was significantly inhibited in A20 overexpressing macrophages (Fig. 4C and D).

The mRNA levels of TNF-α and IL-1β were upregulated in the VEC macrophages induced by LPS and were highest at 1 h. (Fig. 5A and B). This result was the same as the levels of TNF-α and IL-1β measured by ELISA (Fig. 5C and D). However, the levels of TNF-α and IL-1β were significantly inhibited in the A20 overexpressing macrophages.

A20 overexpression increases M polarization from M1 to M2 phenotype. F4/80 and CD206 are expressed in macrophages (27). As presented in Fig. 6, macrophage phenotypes
were investigated using FACs. Macrophage phenotypes M2 and M1 were distinguished by FACS using diverse macrophages markers, F4/80 and CD206 in A20-knockdown and A20-overexpressing NR8383 cells. The present data revealed CD206+ and F4/80+ cells in the A20-overexpressing macrophages in contrast with VEC cells (Fig. 6A and B), and CD206+

Figure 5. Effects of A20 overexpression on TNF-α and IL-1β. mRNA levels of (A) TNF-α and (B) IL-1β were analyzed by reverse transcription quantitative polymerase chain reaction. Protein levels of (C) TNF-α and (D) IL-1β. The data are presented as the mean ± standard deviation. *P<0.05 vs. VEC group. TNF-α, tumor necrosis factor α; IL-1β, interleukin 1β.

Figure 6. A20 overexpression increases macrophage polarization from the M1 to M2 phenotype in the NR8383 cell line following treatment with LPS. Flow cytometric analysis of cells in the (A) VEC and (B) A20 overexpression groups labeled with anti-CD206-APC and antiF4/80-FITC. (C) The percentage of M2 macrophages in the VEC, A20 overexpression, SCR and siA20 groups. Flow cytometric analysis of cells in the (D) SCR, (E) siA20 groups labeled with anti-CD206-APC and antiF4/80-FITC. (F) The percentage of M1 macrophages in the VEC, A20 overexpression, SCR and siA20 groups The percentage of cells stained with CD206 and F4/80 markers was calculated. The results are presented as the mean ± standard deviation (n=3). *P<0.05 vs. the respective control group. LPS, lipopolysaccharide; VEC, vehicle control; SCR, scrambled controlled RNA; siA20, small interfering RNA of A20; APC, allophycocyanin; FITC, fluorescein isothiocyanate.
and F4/80+ A20-knockdown macrophages compared with SRCS (Fig. 6D and E). The CD206+/F4/80+ cells (representing M2 macrophages) and the CD206−/F4/80+ cells (representing M1 macrophages) were assayed by FACS, and it was observed that LPS induced M1 macrophage polarization (Fig. 6C and F). It was concluded that A20-overexpression increased M polarization from the M1 to M2 phenotypes in the NR8383 cells treated with LPS.

Discussion

Macrophage-associated inflammation is a double-edged sword in acute lung injury, owing to its divergent polarization potential. However, molecular mechanisms and potential intervention strategies for macrophage polarization remain obscure. In the present study, the role of A20 protein in the NF-κB signaling pathway, macrophage polarization and acute lung injury, in vitro and in vivo, was demonstrated. The present results suggested that the A20 protein in macrophages could regulate LPS-induced lung injury through the NF-κB signaling pathway. It was further demonstrated that overexpression of A20 may be involved in the M2 polarization of macrophages. Therefore, the present study revealed that the inhibitory effect of A20 on the NF-κB signaling pathway was associated with macrophage polarization.

Excessive activation of the NF-κB signaling pathway in macrophages may induce proinflammatory cytokine production, leading to tissue damage and inappropriate immune responses. In the present study, NF-κB and TNF-α were demonstrated to also be essential in LPS-induced lung injury. A20 is currently considered a negative regulator of inflammation (20,29,30) and has been demonstrated to inhibit NF-κB activity by disrupting the upstream ubiquitin complex (29). Previous studies have demonstrated that A20 inhibits NF-κB activation and is associated with signaling pathways that are induced by TNF-α and IL-1β (30,31). Furthermore, an asthma mouse model demonstrated that A20 could attenuate allergic airway inflammation, which indicates a potential role of A20 in inflammatory lung diseases (32). The results of the present study also suggested that normal lung tissues demonstrated lower levels of A20 mRNA and protein. In addition, LPS stimulation increased the expression of A20, particularly in the early time points following treatment. It was also observed that shortly following in vitro LPS administration, the cultured NR8383 cells exhibited a high level of A20 expression. This indicated that acute injury induced by LPS could induce a rapid upregulation of intracellular A20 protein.

The results of the present study also proved the regulating role of A20 in the NF-κB signaling pathway and cytokine production. A20 was a crucial molecule in the regulation of NF-κB and TNF-α production in macrophages and the immunofluorescent staining demonstrated that A20 was expressed in pulmonary macrophages. Macrophages are involved in a number of immune disorders, and their infiltration into alveoli and release of a variety of proinflammatory cytokines are common pathogenic phenomena in airway inflammation (33). Following treatment with LPS, the level of ubiquitin enzyme A20 in macrophages was elevated but this was not sufficient to downregulate the production of proinflammatory factors, including TNF-α and IL-1β which could be causal cytokines for lung injury. It was also observed that the suppression of A20 induced an increase in the production of these proinflammatory factors in macrophages. The overexpression of A20 resulted in the suppression of NF-κB activation and TNF-α production in macrophages, and therefore, suppressed endothelial hyperpermeability in the lung.

Lung injury induced by LPS could be modulated by the A20 protein in macrophages. Therefore, progression of inflammatory disease may be delayed or inhibited if the activity of NF-κB was effectively inhibited by A20. Taking these results into account, A20-based therapy may be a promising treatment strategy for acute lung injury, as well as other inflammatory diseases.

As NF-κB is associated with macrophage polarization in inflammation, the expression of macrophage markers was also tested (F4/80 and CD206) in the present study. CD206 is a mannose receptor of 175 kDa, a type I membrane protein with a pattern recognition receptor domain of the C-type lectin superfamily. CD206 is expressed on M2 macrophages and serves an essential role in host defense, innate immunity and acquired immunity (15). In the present study, it was concluded that A20-overexpression enhanced macrophage polarization from the M1 to M2 phenotype in NR8383 cells treated with LPS.

Different phenotypes of activated macrophages have different significance in the inflammatory response. M1 macrophages may produce an acute inflammatory response and a large number of invasive inflammatory factors (19). At the same time, M2 macrophages are involved in tissue repair and wound healing, indicating the role of the inflammatory response in repair. A previous study demonstrated that the activation of the NF-κB signaling pathway is involved in the polarization of macrophages (14), which has a role in the immune regulation of ALI. The present study demonstrated that A20 overexpression could promote the polarization of macrophages and demonstrated that A20 could regulate ALI inflammation through the NF-κB signaling pathway. Therefore, A20 may be able to manipulate the polarization of macrophages to alter the level of inflammation and disease outcome. However, further studies are required.

In conclusion, the overexpression of A20 in macrophages may be involved in modulating macrophage polarization in lung injury, implying that A20 may have the potential to be used in interventions for LPS-associated lung disorders.

Acknowledgements

The present study was supported by grants from the National Natural Science Foundation of China (grant nos. 81300055, 81400043 and 81400530) and the Doctoral Fund of the Ministry of Education of China (grant no. 20130071110044). The project was supported by the Shanghai Committee of Science and Technology of China (grant no. 15DZ1930600), and by grant B115 from the Shanghai Leading Academic Discipline Project. Y.S. was supported by the Program for a Professor of Special Appointment (Eastern Scholar) at the Shanghai Institution of Higher Learning and the Key Medical grant from the Science and Technology Commission of Shanghai Municipality (grant nos. 11411951102 and 12JC1402300), and by the State Key Basic Research Program (973) project (grant
no. 2015CB553404). C.B. was supported by the Research Fund for the Doctoral Program of Higher Education of China (grant no. 2011071110054). The authors of the present study would like to thank Mr Lei Gao, the technician of the Pulmonary Department of Zhongshan Hospital, Fudan University, for technical assistance.

References


